Tianyu Co., Ltd. announced that the raw drug siglliptin phosphate of Zhejiang Jingsheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently passed the review by the Drug Evaluation Center of the State Drug Administration. This drug is a hypoglycemic drug, mainly used to treat type 2 diabetes. The company submitted a drug registration application for this ingredient in March 2025 and was accepted. Currently, the API must obtain a notice from the Zhejiang Drug Administration that it “meets the requirements” of the GMP compliance inspection before it can be marketed and sold domestically. There is uncertainty about the domestic marketing and sales time.

Tianyu Co., Ltd. announced that the raw drug siglitine phosphate of Zhejiang Jingsheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently passed the review by the Drug Evaluation Center of the State Drug Administration. This drug is a hypoglycemic drug, mainly used to treat type 2 diabetes. The company submitted a drug registration application for this ingredient in March 2025 and was accepted. Currently, the API must obtain a notice from the Zhejiang Drug Administration that it “meets the requirements” of the GMP compliance inspection before it can be marketed and sold domestically. There is uncertainty about the domestic marketing and sales time.